BGI customers to receive QIAGEN software


Tuesday, 05 May, 2015

QIAGEN and BGI have announced the expansion of their relationship, with QIAGEN’s Ingenuity Variant Analysis software to be provided to customers of BGI’s sequencing services.

Under the reseller agreement, BGI customers will receive sequencing data generated from their samples through Ingenuity Variant Analysis’s secure, cloud-based environment and gain access to its comprehensive gene variant data and genomic interpretation applications. The software will be provided by BGI to customers in China, Hong Kong and Taiwan, with plans to expand to other regions throughout the year.

“We welcome this opportunity to expand our relationship with QIAGEN for the benefit of BGI collaborators around the world,” said BGI Chief Scientist Yingrui Li. “Coupling BGI’s world-class sequencing with the deep bioinformatics of Ingenuity Variant Analysis will give researchers an enhanced, integrated way to seamlessly move quickly from raw data to valuable insights.”

The software quickly filters genetic variants in a cloud-based environment to identify variants most likely to cause disease. The product draws on the Ingenuity Knowledge Base, a repository of expertly curated biological interactions and functional annotations created from millions of individually modelled relationships between proteins, genes, complexes, cells, tissues, drugs and diseases.

“Integrating Ingenuity Variant Analysis into BGI’s highly reliable sequencing services will enable clients to accelerate workflows,” added Laura Furmanski, the head of QIAGEN’s Bioinformatics Business Area. “They’ll be able to transform large quantities of genomic data into valuable molecular insights for research or clinical applications.”

Related News

Air quality expert wins 2025 PM's Prize for Science

Distinguished Professor Lidia Morawska's work in the study of air quality provided vital...

CSL fellowships fund immunity research, AI-designed proteins

Australian scientists Dr Carolien van de Sandt and Dr Rhys Grinter have each been awarded CSL...

Leukaemia Foundation funds ongoing blood cancer research at UWA

The $3m in funding is understood to represent the single largest non-government investment in...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd